JB Capital LLC Decreases Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

JB Capital LLC reduced its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 22.5% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 4,534 shares of the medical research company’s stock after selling 1,320 shares during the quarter. JB Capital LLC’s holdings in Thermo Fisher Scientific were worth $2,804,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in TMO. Advisory Alpha LLC lifted its stake in Thermo Fisher Scientific by 77.4% in the first quarter. Advisory Alpha LLC now owns 779 shares of the medical research company’s stock worth $453,000 after acquiring an additional 340 shares during the period. Advisory Services Network LLC lifted its position in shares of Thermo Fisher Scientific by 2.7% in the 1st quarter. Advisory Services Network LLC now owns 8,869 shares of the medical research company’s stock worth $5,155,000 after purchasing an additional 231 shares during the period. CFO4Life Group LLC purchased a new position in shares of Thermo Fisher Scientific during the first quarter valued at about $234,000. Empirical Finance LLC lifted its holdings in Thermo Fisher Scientific by 3.4% in the first quarter. Empirical Finance LLC now owns 14,143 shares of the medical research company’s stock worth $8,220,000 after buying an additional 467 shares during the period. Finally, Envestnet Portfolio Solutions Inc. raised its position in shares of Thermo Fisher Scientific by 30.2% in the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 45,451 shares of the medical research company’s stock worth $26,417,000 after acquiring an additional 10,547 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Morgan Stanley increased their price objective on Thermo Fisher Scientific from $655.00 to $680.00 and gave the stock an “overweight” rating in a report on Friday, September 20th. Robert W. Baird dropped their price objective on shares of Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. Evercore ISI decreased their target price on shares of Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Barclays cut their price target on Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 23rd. Finally, TD Cowen lifted their price objective on Thermo Fisher Scientific from $656.00 to $686.00 in a research note on Tuesday, October 22nd. Four research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus target price of $649.33.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction on Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the transaction, the senior vice president now owns 12,736 shares in the company, valued at approximately $7,134,197.76. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $554.29, for a total value of $5,542,900.00. Following the completion of the transaction, the chief executive officer now directly owns 121,192 shares in the company, valued at $67,175,513.68. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the sale, the senior vice president now owns 12,736 shares in the company, valued at approximately $7,134,197.76. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 18,150 shares of company stock valued at $10,094,925 over the last 90 days. 0.34% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Stock Performance

TMO traded up $0.78 during trading on Thursday, hitting $560.46. The company’s stock had a trading volume of 91,643 shares, compared to its average volume of 1,454,734. Thermo Fisher Scientific Inc. has a one year low of $437.26 and a one year high of $627.88. The business’s 50 day simple moving average is $596.33 and its 200-day simple moving average is $583.80. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64. The firm has a market cap of $214.38 billion, a PE ratio of 35.09, a P/E/G ratio of 3.67 and a beta of 0.79.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, beating the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The company had revenue of $10.60 billion for the quarter, compared to the consensus estimate of $10.63 billion. During the same period in the previous year, the business earned $5.69 earnings per share. Thermo Fisher Scientific’s quarterly revenue was up .2% compared to the same quarter last year. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 21.68 EPS for the current fiscal year.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.